PainReform Ltd. announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.704 USD | -0.18% | +2.20% | -74.45% |
May. 15 | PainReform Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-74.45% | 1.74M | |
+42.34% | 748B | |
+34.11% | 598B | |
-6.30% | 356B | |
+18.50% | 325B | |
+4.27% | 283B | |
+17.25% | 245B | |
+9.25% | 211B | |
-4.21% | 209B | |
+1.88% | 166B |
- Stock Market
- Equities
- PRFX Stock
- News PainReform Ltd.
- PainReform Ltd. Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy